Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01068613 | Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients | PHASE2 | COMPLETED | 62 | — | — | Jan 1, 2010 | Aug 1, 2010 | Dec 19, 2020 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| QAX028 high dose | EXPERIMENTAL | - |
| QAX028 low dose | EXPERIMENTAL | - |
| Tiotropium | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| QAX028 | DRUG | QAX028 60 mcg via inhalation device |
| Tiotropium | DRUG | Tiotropium via inhalation device |
| Placebo | DRUG | Placebo to QAX028 via inhalation device |
Inclusion Criteria: * Diagnosis of COPD according to GOLD guidelines * Post-bronchodilator 30%≤FEV1\<80% of predicted normal and ost-bronchodilator FEV1/FVC \<0.7 * Smoking history of at least 10 pack years Exclusion Criteria: * Requiring oxygen therapy on a daily basis * Exacerbation of airway d...